Novartis AG vs Southern Copper Corp — how do they compare? Novartis AG trades at $153.88 (market cap $290.25B), while Southern Copper Corp trades at $188.02 (market cap $146.07B). The key difference: Novartis AG is the larger of the two by market cap, and Novartis AG pays the higher dividend (3.17%). Which is the better fit depends on your goals.
| NVS | SCCO | |
|---|---|---|
Market Cap | $290.25B | $146.07B |
Sector | Health | Basic Materials |
52-Week High | $168.62 | $218.85 |
52-Week Low | $113.50 | $90.54 |
Enterprise Value | $330.27B | $148.12B |
Dividend Yield | 3.17% | 2.28% |
Signals from Pluang's Aura AI — not financial advice
Novartis (NVS) trades at $153.87, showing minimal daily movement with a slight 0.07% gain. The stock exhibits bearish technical signals from moving averages despite a neutral oscillator reading. Fundamentally, the company reported strong Q2 2026 earnings that beat expectations, with revenue of $56.67 billion in 2025 and robust profitability margins, including a net income margin of 23.92%. Recent news highlights successful drug launches offsetting generic competition pressures.
The outlook remains cautiously optimistic as new medicines drive growth, but risks include patent expirations and pipeline trial results. Analyst sentiment is mixed with 68% hold ratings, reflecting balanced views on execution versus competitive threats. Investment appeal hinges on sustained drug innovation and margin stability amid industry headwinds.
SCCO trades at $188.01, up 9.0% today, with a neutral technical signal and strong fundamentals including a 34.13% net income margin and robust cash flow. Recent earnings beats and positive news on copper demand from AI data centers highlight growth potential, though the stock trades above the consensus price target of $152.79.
Outlook is mixed: strong profitability and sector tailwinds support upside, but high valuation ratios and analyst caution pose risks. Investors should weigh earnings consistency against premium pricing and market volatility.
Trailing returns across standard periods
Latest headlines on both assets
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →Southern Copper Corp is an integrated producer of copper and other minerals and operates the mining, smelting, and refining facilities in Peru and Mexico. Its production includes copper, molybdenum, zinc, and silver. The company operates through the following segments: Peruvian operations, Mexican open-pit operations, and Mexican underground mining operations. Southern Copper generates the majority of its revenue from the sale of copper and the rest from the sale of non-copper products, such as molybdenum, silver, zinc, lead, and gold. Its geographical segments are The Americas, Europe, and Asia.
Read more on SCCO →